Pharma Mar stock

PHM · BME · EUR

Compare Pharma Mar
€67.30Change from previous close: +0.07%Absolute change: +€0.05

Close · November 16, 2026

Price history

−11.04% over the period

1 year: from €75.65 (November 17, 2025) to €67.30 (November 16, 2026), −11.04%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€67.30
October 30, 2026€67.50
September 30, 2026€73.10
August 31, 2026€81.35
July 31, 2026€79.05
June 30, 2026€75.45
May 29, 2026€100.00
April 30, 2026€96.00
March 31, 2026€87.40
February 27, 2026€80.25
January 30, 2026€78.95
December 31, 2025€74.90
November 28, 2025€75.25
November 17, 2025€75.65

At a glance

  • The company

    Biopharmaceutical company focused on researching, developing and commercializing cancer treatments and gene-silencing therapies

  • Latest results

    Quarter to June 30, 2026 · EPS -€0.06 (estimate €0.18)

TickerLandia's take on Pharma Mar

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€62.00
52-wk high€105.20

−36.03% from the 52-week high

Analysts · 8 analysts

Average target€100.56+49.42% vs. price

Buy 6 · Hold 2 · Sell 0

TickerLandia Fingerprint: Pharma Mar

Compared with similar companies: very weak momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Pharma Mar is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Pharma Mar's P/E today is 15.7, in line with the median of its last 5 fiscal years (17.4; between 9.48 and 53.6 from 2020 to 2025). Pharma Mar's P/E (trailing 12 months): 17.2, +41% against the median of a group of 7 similar companies (12.2).

P/E compared with its history

Compared with 7 similar companies

Pharma Mar's metrics compared with similar companies
MetricPharma MarPosition in the groupBand
P/E (trailing 12 months)17.2Middle
Forward P/E13.7Low
Operating margin21.3%Middle
ROE31.5%High
Debt/equity0.30Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Pharma Mar. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€49.61M

Latest quarter · Q2 2026

Net income

-€972K

Latest quarter · Q2 2026

Quarterly net margin

-2.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€1.17B
P/E
17.2
EPS
€3.93
Volume
4.31K
Daily trading
€2.75M
Dividend yield
1.49%
Last ex-dividend on July 8, 2026

How Pharma Mar is changing

All results
  • Revenue fell 3.9% a year on average over the last 5 years

  • Operating margin rose from 21.4% to 27.4%

  • Less cash than profit: free cash flow equal to 9% of net income

Returns

Pharma Mar returns with dividends

€1,000 invested in Pharma Mar 5 years ago, on November 16, 2021, would be worth €1,174 today with dividends reinvested: +17.45% in total, +3.27% per year. On price alone it would be €1,097 (+9.68%).

PeriodPharma MarIBEX 35€1,000 becomes
1 month−0.88%+4.21%€991
6 months−30.11%+13.60%€699
Year to date−10.15%+15.67%€899
1 year−9.95%+23.79%€901
3 years+87.65%+107.09%€1,876
5 years+17.45%+121.46%€1,174
10 years+119.07%+131.75%€2,191

Over the last 6 months it has done better than 2% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. IBEX 35: price only. Calculate your investment

The chart in detail

Pharma Mar: technical analysis

Pharma Mar is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 78.0% below its all-time closing high (€306.00, October 6, 2000).

Trend
Downward
RSI (14 sessions)
45
Between 30 and 70
vs 200-session average
−17.20%

Support and resistance

Price areas where Pharma Mar has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€78.48+16.62%3 touches, last on February 10, 2026
  2. Resistance€74.31+10.42%4 touches, last on August 6, 2026
  3. Resistance€72.55+7.80%2 touches, last on December 18, 2025
  4. Last price€67.30
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved less than the IBEX 35.

Beta (1 year) vs IBEX 35
0.46
Volatility (60 sessions, annualised)
25.7%
Largest fall in the last year
−37.98%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Pharma Mar: seasonality

Average monthly price change over 27 years

+5.9%Jan+0.5%Feb+0.3%Mar+5.5%Apr+1.0%May−4.9%Jun−1.0%Jul+2.7%Aug+0.3%Sep+0.9%Oct−2.9%Nov−2.3%Dec

Over the last 27 years, the strongest month for Pharma Mar has been January: +5.91% on average, positive in 19 years out of 26. The weakest has been June: −4.89% on average, positive in 7 years out of 26. November, the current month, has been positive in 9 years out of 26 (−2.86% on average).

Show chart data
MonthAverageMedianPositive years
January+5.91%+5.81%19 of 26
February+0.50%−0.95%12 of 26
March+0.28%+0.08%13 of 26
April+5.46%+1.73%16 of 26
May+0.97%+2.35%15 of 26
June−4.89%−5.69%7 of 26
July−0.96%−0.64%13 of 26
August+2.68%−0.12%13 of 26
September+0.27%−1.30%13 of 26
October+0.86%−0.30%13 of 27
November−2.86%−1.13%9 of 26
December−2.34%−1.55%9 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Pharma Mar and its competitors

Pharma Mar, S.A. is based in Madrid, Spain, where it was incorporated in 1986. The biopharmaceutical company researches, develops, produces and commercializes bio-active compounds for oncology, selling its treatments in Spain, Germany, Ireland, France, Switzerland, the rest of the European Union, the United States and other markets. Its best-known products include Yondelis, for soft tissue sarcoma and ovarian cancer, Zepzelca, for small cell lung cancer, and Aplidin, for multiple myeloma.

Headquarters
Madrid, Spain
Employees
505
Founded
1986
Chief executive
Jose Fernandez Sousa-Faro
Pharma Mar and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Pharma MarPHM$1.29B21.3%17.2−30.11%
IdorsiaIDIA$1.26B-68.4%—−10.71%
Basilea PharmaceuticaBSLN$1.07B24.2%18.1+31.94%
PhilogenPHIL$920.79M79.1%4.01−7.33%
InventivaIVA$895.83M-5,980.9%—−27.86%
Pharming GroupPHARM$892.54M12.8%38.0+3.70%

Same industry or related industries, similar size. Compare Pharma Mar with its competitors · Full profile